Commercialisation & Medical Affairs

Nicole Dale

Could q-CAR Redefine Drug Discovery?

Pharmatica image for q-CAR drug discovery showing dynamic protein conformations, ligand binding, and AI-driven molecular analysis.

Find out how q-CAR drug discovery moves beyond static protein structures by linking protein dynamics, ligand activity, and AI to precision drug design.

Nicole Dale

FDA 2026 Draft Guidance on Alternatives to Animal Testing

Illustration representing FDA alternatives to animal testing, featuring laboratory research, organ-on-chip technology, genetic science, AI-enabled drug discovery and next-generation pharmaceutical testing methods.

The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.

Nicole Dale

Optimising Preclinical Pharmacology for Oncology NMEs

Oncology researcher performing preclinical pharmacology testing for new molecular entities (NMEs), illustrating oncology drug development, translational research, biomarker discovery, and advanced preclinical model optimisation.

Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.

Nicole Dale

Success for Non-Animal Testing of Preclinical Toxicity?

Pharmatica hyper-realistic image of a human organ-on-chip platform with cultured cells used for non-animal testing in drug discovery in order to determine preclinical toxicity in a pharmaceutical research laboratory.

Can non-animal testing methods be used in preclinical drug discovery? Here is what the evidence is for their accuracy and limits assessing preclinical toxicity.

Nicole Dale

Strategic Pharma Intelligence Drives Better Decisions in Life Sciences

Strategic pharma intelligence concept featuring Pharmatica branding, molecular structures, global business leaders in discussion, and pharmaceutical innovation imagery, representing data-driven decision-making, industry analysis, and executive strategy in the life sciences sector.

Find out why strategic pharma intelligence is needed to connect insights and to guide confident decision-making across the drug development lifecycle.

Nicole Dale

Why the U.S. Medicine Supply Chain Is One Shortage Away from Crisis

The USP's 2025 Vulnerable Medicines List flags 100 drugs at high risk. Here is what to do to build pharma supply chain resilience.